AXSM - Axsome Therapeutics, Inc.

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
3.98
-0.17 (-4.10%)
As of 10:20AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close4.15
Open4.20
Bid4.00 x 1000
Ask4.03 x 800
Day's Range3.90 - 4.27
52 Week Range2.05 - 5.95
Volume87,641
Avg. Volume224,020
Market Cap116.292M
Beta (3Y Monthly)-0.15
PE Ratio (TTM)N/A
EPS (TTM)-1.09
Earnings DateNov 6, 2018 - Nov 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est20.00
Trade prices are not sourced from all markets
  • GlobeNewswire4 days ago

    Axsome Therapeutics Hosts R&D Day Today with Key Opinion Leaders Focusing on AXS-05 and Unmet Needs in Alzheimer’s Disease Agitation

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, is hosting a research and development (R&D) day in New York City today with key opinion leaders (KOLs), to highlight AXS-05, the company’s most advanced CNS product candidate, and unmet needs in agitation associated with Alzheimer’s disease (AD). “We are honored to host two renowned leaders in the field of Alzheimer’s disease agitation research who will discuss the condition and the current treatment landscape” said Herriot Tabuteau, MD, Chief Executive Officer of Axsome. “Alzheimer’s disease agitation is a serious and distressing condition for which there is currently no approved treatment.

  • GlobeNewswire5 days ago

    Axsome Therapeutics Receives FDA Orphan Drug Designation for AXS-12 for the Treatment of Narcolepsy

    Narcolepsy is a serious, debilitating, neurological condition characterized by excessive daytime sleepiness and cataplexy, which is a sudden reduction or loss of muscle tone while a patient is awake. Yesterday morning, Axsome announced that it plans to initiate a Phase 2 trial of AXS-12 for the treatment of the symptoms of narcolepsy in the fourth quarter of this year with top-line results anticipated in the first half of 2019. “We are very pleased to have received Orphan Drug Designation from the FDA for AXS-12 on the heels of our recent announcement of this new CNS product candidate for the treatment of narcolepsy,” said Herriot Tabuteau, M.D., Chief Executive Officer of Axsome.

  • GlobeNewswire6 days ago

    Axsome Therapeutics to Host Call Today with Key Opinion Leader Focusing on AXS-12 and Unmet Needs in Narcolepsy

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, is hosting a conference call and webcast with slides today at 8:00 AM Eastern Time with a key opinion leader (KOL) focusing on AXS-12 (reboxetine) and unmet needs in narcolepsy. Additional information on AXS-12, the Company’s new product candidate for the treatment of the symptoms of narcolepsy can be found in a separate related release issued this morning. The call and webcast will feature a presentation from Dr. Michael J. Thorpy who will discuss the clinical features of and current treatment landscape for narcolepsy.

  • GlobeNewswire6 days ago

    Axsome Therapeutics Announces AXS-12 for the Treatment of Narcolepsy

    NEW YORK, Oct. 16, 2018 (GLOBE NEWSWIRE) --  Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced its next CNS product candidate, AXS-12 (reboxetine), which the Company is developing for the treatment of narcolepsy. Narcolepsy is a serious, debilitating, orphan neurological condition characterized by excessive daytime sleepiness and cataplexy.

  • GlobeNewswire10 days ago

    Axsome Therapeutics to Present at Upcoming Investor Conferences

    Dr. Tabuteau will present a corporate overview. A live webcast of this event can be viewed on the company’s website at www.axsome.com. Dr. Tabuteau will participate in the Therapeutic Achievements for CNS Disorders panel.

  • GlobeNewswire11 days ago

    Axsome Therapeutics to Focus on Growing Core CNS Portfolio; Establishes Axsome Pain and Primary Care Business Unit to Enhance Value of Non-CNS Assets

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it will focus on its growing core CNS portfolio. As a result, the Company has created Axsome Pain and Primary Care (Axsome PPC), a new business unit to house, manage, develop and enhance the value of Axsome’s non-CNS assets.

  • GlobeNewswire24 days ago

    Axsome Therapeutics Announces $8.9 Million Registered Direct Offering

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it has entered into a definitive purchase agreement with certain existing and other institutional accredited investors to purchase in a registered direct offering 2,966,667 shares of its common stock at a purchase price of $3.00 per share. Participating investors include Armistice Capital, Lincoln Park Capital, and Sio Capital Management. The net proceeds from the offering are expected to be approximately $8.8 million.

  • Simply Wall St.26 days ago

    What Does Axsome Therapeutics Inc’s (NASDAQ:AXSM) Ownership Structure Look Like?

    Every investor in Axsome Therapeutics Inc (NASDAQ:AXSM) should be aware of the most powerful shareholder groups. Institutions often own shares in more established companies, while it’s not unusual to see Read More...

  • GlobeNewswire28 days ago

    Axsome Therapeutics to Present at Upcoming Investor Conferences

    NEW YORK, Sept. 24, 2018-- Axsome Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system disorders, today announced that ...

  • GlobeNewswirelast month

    Axsome Therapeutics to Host R&D Day with Key Opinion Leaders Focused on AXS-05 and Unmet Needs in Alzheimer’s Disease Agitation

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it will host a research and development (R&D) day with key opinion leaders (KOLs) on Thursday, October 18, 2018 in New York City. The event will highlight AXS-05, the company’s most advanced CNS product candidate, and unmet needs in agitation associated with Alzheimer’s disease (AD). AXS-05 is in a Phase 2/3 randomized, double-blind, controlled trial (the ADVANCE-1 study) in patients with agitation associated with AD.

  • GlobeNewswire2 months ago

    Axsome Therapeutics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that Herriot Tabuteau, MD, Axsome’s Chief Executive Officer, will present a corporate overview at the 20th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC., on September 5, 2018 at 2:10 PM Eastern Time. The convention will be held at the St. Regis New York Hotel in New York, NY. A live webcast of the event can be viewed on the company’s website at www.axsome.com.

  • Associated Press2 months ago

    Axsome: 2Q Earnings Snapshot

    On a per-share basis, the New York-based company said it had a loss of 32 cents. The company's shares closed at $2.63. A year ago, they were trading at $5.70. _____ This story was generated by Automated ...

  • GlobeNewswire2 months ago

    Axsome Therapeutics Reports Second Quarter 2018 Financial Results and Provides Business Update

    Interim analysis results from two Phase 3 trials and topline results from one Phase 2 trial of AXS-05 anticipated in 4 Q 2018. Phase 3 trial of AXS-07 in acute migraine anticipated to start in 4 Q 2018. ...

  • ACCESSWIRE2 months ago

    Axsome Therapeutics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Axsome Therapeutics, Inc. (NASDAQ: AXSM ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 8:00 AM Eastern ...

  • GlobeNewswire3 months ago

    Axsome Therapeutics to Report Second Quarter 2018 Financial Results on August 8, 2018

    Axsome Therapeutics, Inc. (AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous system (CNS) disorders, today announced that it will report its financial results for the second quarter of 2018 on Wednesday, August 8, 2018 before the opening of the U.S. financial markets. AXS-02 is currently in a Phase 3 trial in knee osteoarthritis (OA) associated with bone marrow lesions (BMLs) with an additional Phase 3 trial planned in chronic low back pain (CLBP) associated with Modic changes (MCs).

  • Is Axsome Therapeutics Inc’s (NASDAQ:AXSM) CEO Incentives Align With Yours?
    Simply Wall St.5 months ago

    Is Axsome Therapeutics Inc’s (NASDAQ:AXSM) CEO Incentives Align With Yours?

    Leading Axsome Therapeutics Inc (NASDAQ:AXSM) as the CEO, Herriot Tabuteau took the company to a valuation of US$83.04M. Recognizing whether CEO incentives are aligned with shareholders is a crucial partRead More...

  • Associated Press5 months ago

    Axsome: 1Q Earnings Snapshot

    On a per-share basis, the New York-based company said it had a loss of 19 cents. The company's shares closed at $3.35. A year ago, they were trading at $3.90. _____ This story was generated by Automated ...

  • ACCESSWIRE5 months ago

    Axsome Therapeutics, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 8, 2018 / Axsome Therapeutics, Inc. (NASDAQ: AXSM ) will be discussing their earnings results in their Q1 Earnings Call to be held on May 8, 2018 at 8:00 AM Eastern Time. ...